Drugs / CMV-MVA Triplex
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06075745 | Mar 2024 → Jun 2027 expected | — | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05099965 Comparator | Nov 2021 → Nov 2024 | HIV infectious disease, cytomegalovirus infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMV-MVA Triplex | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05099965 ↗ |
| Known as | Triplex | “A5355 was a randomized, placebo-controlled study conducted at US sites to evaluate the safety and immunogenicity of two injections of the study drug Modified Vaccinia Ankara...” NCT05099965 ↗ |
| Modality | Vaccine | “MVA-based anti-Cytomegalovirus (CMV) Vaccine” NCT05099965 ↗ |
| Route | Intramuscular | “by intramuscular (IM) deltoid injections” NCT05099965 ↗ |